Sensory-Neuron and Microglial CB2 Deletions Produced Different Pain Findings
A mouse study localized selected cannabinoid benefits to sensory-neuron CB2 receptors rather than the tested microglial/macrophage population. A receptor’s presence in several tissues does not show that each tissue mediates the same effect.
Selective deletion tested necessity
Researchers used paclitaxel-induced neuropathy and conditional receptor deletions. Experimental agonists LY2828360 and AM1710 reduced hypersensitivity in controls; efficacy was lost after sensory-neuron CB2 deletion. The tested microglial/macrophage deletion did not remove the corresponding benefit.
The sex result narrowed opioid claims
LY2828360’s morphine-tolerance-sparing effect appeared in males but not females under the reported conditions. Effects on hypersensitivity and opioid adaptation therefore should not be collapsed into one sex-independent treatment claim.
A mechanism is not a cannabis prescription
These drugs were selective experimental agonists, not cannabis or THC preparations. Conditional deletion supports necessity within the model, not sufficiency in every pain condition. Paclitaxel injury, injected dosing and mouse behavioral endpoints limit transfer to patients. The findings also do not show that microglia are irrelevant to pain generally, only that the tested CB2 population was not required for these particular effects.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Cannabinoid CB2 receptors in primary sensory neurons are implicated in CB2 agonist-mediated suppression of paclitaxel-induced neuropathic nociception and sexually-dimorphic sparing of morphine tolerance. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2024). DOI: 10.1016/j.biopha.2024.116879.
